Business
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by European Commission (EC)
TOKYO & HYOGO, Japan, June 24, 2025--JCR and MEDIPAL announced that the EC has granted ODD to JR-446, an investigational drug for the treatment of mucopolysaccharidosis type IIIB.
About this update from Jcr Pharmaceuticals Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":251,"url":"https://media.zenfs.com/en/business-wire.com/c3480b68f774b2c33225c8eece61f1cd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WexFXOhmDQX1Ua.Ye09t4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c3480b68f774b2c33225c8eece61f1cd","width":480,"height":251}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/267b7f25407fdbad67275f301f3da8ea"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/T1gQEtwK8PYJpe4Tj5GwhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/267b7f25407fdbad67275f301f3da8ea","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/RrwzxT39w7cIZX.xeSgoqw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/267b7f25407fdbad67275f301f3da8ea","width":1024,"height":512}}},{"type":"text","content":"TOKYO & HYOGO, Japan, June 24, 2025--(BUSINESS WIRE)--MEDIPAL HOLDINGS CORPORATION (TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd. (TSE 4552, JCR) today announced that the European Commission (EC) has granted orphan drug designation (ODD) to JR-446, an investigational drug for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB or Sanfilippo syndrome type B), following the recent the U.S. Food and Drug Administration (FDA) designation.1","length":457,"tagName":"p"},{"type":"text","content":"MPS IIIB affects an estimated 500 to 1,000 individuals worldwide,2 causing severe central nervous system (CNS) symptoms. Despite the dire need, there are currently no approved treatments available for this condition. JR-446, developed using JCR’s proprietary J-Brain Cargo® technology, has shown promising non-clinical results in addressing the CNS symptoms of this challenging disorder, and it is currently being studied in a Phase I/II trial that is being conducted in Japan (JR-446-101) under a collaboration agreement between the two companies.","length":548,"tagName":"p"},{"type":"text","content":"In September 202...